does medicaid cover glp 1 drugs for weight loss Rhode Island considers ending coverage of GLP-1 • Rhode Island Current More states consider dropping GLP-1

### Funding Statement SDL and AC were supported by the National Science Foundation (Grant Nos.\ CAREER DMS-1944574 and DMS-2325258) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained

With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management

other outcomes were cardiovascular and total death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for heart failure (HHF), and renal outcome

Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.

This is the unlikely journey from desert predator to medical marvel.

This Comment highlights emerging evidence and advocates for clinical strategies that prioritize muscle preservation to ensure the long-term success and safety of pharmacological weight management.